Assessment of a rapid pan-antibody dot test for detection of antibodies against SARS-CoV-2

Authors

  • Md Ahsanul Haq Gonoshasthaya-RNA Molecular Diagnostic and Research Center, Dhaka, Bangladesh
  • Maha Jamiruddin Gonoshasthaya-RNA Molecular Diagnostic and Research Center, Dhaka, Bangladesh
  • Mohib Ullah Khondoker Gonoshasthaya-RNA Molecular Diagnostic and Research Center, Dhaka, Bangladesh
  • Md Firoz Ahmed Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh
  • Shahad Saif Khandker Gonoshasthaya-RNA Molecular Diagnostic and Research Center, Dhaka, Bangladesh
  • Tamanna Ali Gonoshasthaya-RNA Molecular Diagnostic and Research Center, Dhaka, Bangladesh
  • Mamun Mostafi Gonoshasthaya Samaj Vittik Medical College, Savar, Dhaka, Bangladesh and Center for Multidisciplinary Research, Gono Bishwabidyalay, Savar, Dhaka, Bangladesh
  • Bijon Kumar Sil Gonoshasthaya-RNA Molecular Diagnostic and Research Center, Dhaka, Bangladesh
  • Nihad Adnan Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh
  • Mohd Raeed Jamiruddin Department of Pharmacy, BRAC University, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/bjms.v20i5.55407

Keywords:

Cross-sectional study; SARS-CoV-2; seroepidemiological study; immunoblotting; herd-immunity; antibodies.

Abstract

Background: With the drastic spread of COVID-19 and mass mortality of people globally, detection of the progression of this disease has stood out to be a necessity. Hence, we set out to identify the prevalence of COVID-19 antibodies in Bangladesh using the in-house rapid pan-immunoglobulin dot-blot test kit and evaluate the performance of this kit.

Methods: In this cross-sectional study, we tested serum collected between mid-May and mid-June 2020 for COVID-19 antibodies by using the in-house rapid pan-immunoglobulin dot-blot test kit in RTPCR confirmed patients with symptoms for 1-7 days (Group Ia; n =100) and 8-14 days (Group Ib; n = 100); symptomatic RT-PCR negative patients (Group II; n = 100) and convalescent patients (Group III; n = 109) while comparing with pre-pandemic sera samples collected prior two years to December-2019 (Group IV; n = 100).

Results: Our kit detected that almost 70% of the convalescent patients produced antibodies against COVID-19 compared to other groups. However, the group with individuals at the end phase of COVID-19 exhibited the second-highest percentage of seroprevalence (41%). We also observed that though Group II was RT-PCR negative, 20% of them showed COVID-19 antibodies.

Conclusion: With a specificity of 96% in our kit, we can say that our kit will be a potential device for the detection of SARS-CoV-2 antibodies and to understand herd immunity in Bangladesh.

Bangladesh Journal of Medical Science Vol.20(5) 2021 p.131-139

Downloads

Download data is not yet available.
Abstract
128
PDF
79

Downloads

Published

2021-09-05

How to Cite

Haq, M. A. ., Jamiruddin, M. ., Khondoker, M. U. ., Ahmed, M. F., Khandker, S. S., Ali, T., Mostafi, M. ., Sil, B. K. ., Adnan, N. ., & Jamiruddin, M. R. . (2021). Assessment of a rapid pan-antibody dot test for detection of antibodies against SARS-CoV-2. Bangladesh Journal of Medical Science, 20(5), 131–139. https://doi.org/10.3329/bjms.v20i5.55407

Issue

Section

Original Articles